U.S. Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Mode (Contract, In-house), By Application, By End-use, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                     1.1. Market Segmentation & Scope
                     1.2. Segment Definitions
                         1.2.1. Technology
                         1.2.2. Delivery Method
                         1.2.3. Mode
                         1.2.4. Application
                         1.2.5. End-use
                         1.2.6. Estimates and forecasts timeline
                     1.3. Research Methodology
                     1.4. Information Procurement
                         1.4.1. Purchased database
                         1.4.2. GVR’s internal database
                         1.4.3. Secondary sources
                         1.4.4. Primary research
                         1.4.5. Details of primary research
                             1.4.5.1. Data for primary interviews in U.S.
                     1.5. Information or Data Analysis
                         1.5.1. Data analysis models
                     1.6. Market Formulation & Validation
                     1.7. Model Details
                         1.7.1. Commodity flow analysis (Model 1)
                         1.7.2. Approach 1: Commodity flow approach
                     1.8. List of Secondary Sources
                     1.9. List of Primary Sources
                     1.10. Objectives
Chapter 2. Executive Summary
                     2.1. Market Outlook
                     2.2. Segment Outlook
                         2.2.1. Technology Outlook
                         2.2.2. Delivery Method Outlook
                         2.2.3. Mode Outlook
                         2.2.4. Application Outlook
                         2.2.5. End-use Outlook
                     2.3. Competitive Insights
Chapter 3. U.S. Genome Editing Market Variables, Trends & Scope
                     3.1. Market Lineage Outlook
                         3.1.1. Parent market outlook
                         3.1.2. Related/ancillary market outlook
                     3.2. Market Dynamics
                         3.2.1. Market driver analysis
                             3.2.1.1. Success in pre-clinical models drives demands for genome editing therapeutics
                             3.2.1.2. Rising competition amongst market participants for business development
                             3.2.1.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
                             3.2.1.4. Increasing demand for synthetic genes and genetically modified organisms
                             3.2.1.5. Technological advancements in gene editing technologies
                             3.2.1.6. Rising adoption in agricultural biotechnology
                         3.2.2. Market restraint analysis
                             3.2.2.1. Challenges with respect to clinical translation
                             3.2.2.2. Regulatory, scientific, and ethical challenges pertaining to the use of genetically modified products
                             3.2.2.3. Off-target effects of CRISPR technology
                     3.3. U.S. Genome Editing Market Analysis Tools
                         3.3.1. Industry Analysis - Porter’s Five Forces
                             3.3.1.1. Threat of new entrant
                             3.3.1.2. Threat of substitutes
                             3.3.1.3. Bargaining power of buyers
                             3.3.1.4. Bargaining power of suppliers
                             3.3.1.5. Competitive rivalry
                         3.3.2. PESTEL Analysis
                             3.3.2.1. Political & legal landscape
                             3.3.2.2. Economic landscape
                             3.3.2.3. Social landscape
                             3.3.2.4. Technological landscape
                             3.3.2.5. Environmental landscape
Chapter 4. U.S. Genome Editing Market: Technology Estimates & Trend Analysis
                     4.1. U.S. Genome Editing Market: Technology Dashboard
                     4.2. U.S. Genome Editing Market: Technology Movement Analysis
                     4.3. U.S. Genome Editing Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     4.4. Meganucleases
                         4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     4.5. (CRISPR)/Cas9
                         4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     4.6. TALENs/MegaTALs
                         4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     4.7. ZFN
                         4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     4.8. Others
                         4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Genome Editing Market: Delivery Method Estimates & Trend Analysis
                     5.1. U.S. Genome Editing Market: Delivery Method Dashboard
                     5.2. U.S. Genome Editing Market: Delivery Method Movement Analysis
                     5.3. U.S. Genome Editing Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     5.4. Ex-vivo
                         5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     5.5. In-vivo
                         5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Genome Editing Market: Mode Estimates & Trend Analysis
                     6.1. U.S. Genome Editing Market: Mode Dashboard
                     6.2. U.S. Genome Editing Market: Mode Movement Analysis
                     6.3. U.S. Genome Editing Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     6.4. Contract
                         6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     6.5. In-house
                         6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Genome Editing Market: Application Estimates & Trend Analysis
                     7.1. U.S. Genome Editing Market: Application Dashboard
                     7.2. U.S. Genome Editing Market: Application Movement Analysis
                     7.3. U.S. Genome Editing Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     7.4. Genetic Engineering
                         7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                         7.4.2. Cell Line Engineering
                             7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                         7.4.3. Animal Genetic Engineering
                             7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                         7.4.4. Plant Genetic Engineering
                             7.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                         7.4.5. Others
                             7.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     7.5. Clinical Applications
                         7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                         7.5.2. Diagnostics
                             7.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                         7.5.3. Therapy Development
                             7.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. Genome Editing Market: End-use Estimates & Trend Analysis
                     8.1. U.S. Genome Editing Market: End-use Dashboard
                     8.2. U.S. Genome Editing Market: End-use Movement Analysis
                     8.3. U.S. Genome Editing Market Size & Forecasts and Trend Analyses, 2018 to 2030
                     8.4. Biotechnology & Pharmaceutical Companies
                         8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     8.5. Academic & Government Research Institutes
                         8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                     8.6. Contract Research Organizations
                         8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
                     9.1. Recent Developments & Impact Analysis, By Key Market Participants
                     9.2. Company/Competition Categorization
                     9.3. Vendor Landscape
                         9.3.1. List of key distributors and channel partners
                         9.3.2. Key customers
                         9.3.3. Key company market share analysis, 2023
                         9.3.4. Merck KGaA
                             9.3.4.1. Company overview
                             9.3.4.2. Financial performance
                             9.3.4.3. Product benchmarking
                             9.3.4.4. Strategic initiatives
                         9.3.5. Cibus
                             9.3.5.1. Company overview
                             9.3.5.2. Financial performance
                             9.3.5.3. Product benchmarking
                             9.3.5.4. Strategic initiatives
                         9.3.6. Recombinetics, Inc.
                             9.3.6.1. Company overview
                             9.3.6.2. Financial performance
                             9.3.6.3. Product benchmarking
                             9.3.6.4. Strategic initiatives
                         9.3.7. Sangamo
                             9.3.7.1. Company overview
                             9.3.7.2. Financial performance
                             9.3.7.3. Product benchmarking
                             9.3.7.4. Strategic initiatives
                         9.3.8. Editas Medicine
                             9.3.8.1. Company overview
                             9.3.8.2. Financial performance
                             9.3.8.3. Product benchmarking
                             9.3.8.4. Strategic initiatives
                         9.3.9. Precision Biosciences
                             9.3.9.1. Company overview
                             9.3.9.2. Financial performance
                             9.3.9.3. Product benchmarking
                             9.3.9.4. Strategic initiatives
                         9.3.10. CRISPR Therapeutics
                             9.3.10.1. Company overview
                             9.3.10.2. Financial performance
                             9.3.10.3. Product benchmarking
                             9.3.10.4. Strategic initiatives
                         9.3.11. Intellia Therapeutics, Inc.
                             9.3.11.1. Company overview
                             9.3.11.2. Financial performance
                             9.3.11.3. Product benchmarking
                             9.3.11.4. Strategic initiatives
                         9.3.12. Caribou Biosciences, Inc.
                             9.3.12.1. Company overview
                             9.3.12.2. Financial performance
                             9.3.12.3. Product benchmarking
                             9.3.12.4. Strategic initiatives
                         9.3.13. Cellectis S.A.
                             9.3.13.1. Company overview
                             9.3.13.2. Financial performance
                             9.3.13.3. Product benchmarking
                             9.3.13.4. Strategic initiatives
                         9.3.14. GenScript
                             9.3.14.1. Company overview
                             9.3.14.2. Financial performance
                             9.3.14.3. Product benchmarking
                             9.3.14.4. Strategic initiatives
                         9.3.15. AstraZeneca
                             9.3.15.1. Company overview
                             9.3.15.2. Financial performance
                             9.3.15.3. Product benchmarking
                             9.3.15.4. Strategic initiatives
                         9.3.16. Integrated DNA Technologies, Inc.
                             9.3.16.1. Company overview
                             9.3.16.2. Financial performance
                             9.3.16.3. Product benchmarking
                             9.3.16.4. Strategic initiatives
                         9.3.17. Egenesis Inc.
                             9.3.17.1. Company overview
                             9.3.17.2. Financial performance
                             9.3.17.3. Product benchmarking
                             9.3.17.4. Strategic initiatives
                         9.3.18. New England Biolabs
                             9.3.18.1. Company overview
                             9.3.18.2. Financial performance
                             9.3.18.3. Product benchmarking
                             9.3.18.4. Strategic initiatives
                         9.3.19. OriGene Technologies, Inc.
                             9.3.19.1. Company overview
                             9.3.19.2. Financial performance
                             9.3.19.3. Product benchmarking
                             9.3.19.4. Strategic initiatives
                         9.3.20. Lonza
                             9.3.20.1. Company overview
                             9.3.20.2. Financial performance
                             9.3.20.3. Product benchmarking
                             9.3.20.4. Strategic initiatives
                         9.3.21. Thermo Fisher Scientific, Inc.
                             9.3.21.1. Company overview
                             9.3.21.2. Financial performance
                             9.3.21.3. Product benchmarking
                             9.3.21.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. Genome Editing Market, by Technology, 2018 - 2030 (USD Million)
Table 3 U.S. Genome Editing Market, by Delivery Method, 2018 - 2030 (USD Million)
Table 4 U.S. Genome Editing Market, by Mode, 2018 - 2030 (USD Million)
Table 5 U.S. Genome Editing Market, by Application, 2018 - 2030 (USD Million)
Table 6 U.S. Genome Editing Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 U.S. Genome Editing Market Segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 End-use and end-use segment snapshot
Fig. 10 Sales channel and age segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Market dynamics
Fig. 13 Porter’s Five Forces analysis
Fig. 14 PESTLE analysis
Fig. 15 U.S. genome editing market: Technology outlook and key takeaways
Fig. 16 U.S. genome editing market: Technology movement analysis
Fig. 17 Meganucleases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 (CRISPR)/Cas9 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 TALENs/MegaTALs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 ZFN market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 U.S. genome editing market: Delivery method outlook and key takeaways
Fig. 23 U.S. genome editing market: Delivery method movement analysis
Fig. 24 Ex-vivo market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 In-vivo market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 U.S. genome editing market: Mode outlook and key takeaways
Fig. 27 U.S. genome editing market: Mode movement analysis
Fig. 28 Contract market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 In-house market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 U.S. genome editing market: Application outlook and key takeaways
Fig. 31 U.S. genome editing market: Application movement analysis
Fig. 32 Genetic engineering market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Cell line engineering market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Animal genetic engineering market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Plant genetic engineering market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Clinical applications market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Therapy development market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 U.S. genome editing market: End-use outlook and key takeaways
Fig. 41 U.S. genome editing market: End-use movement analysis
Fig. 42 Biotechnology & pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Academic & government research institutes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Contract research organizations market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Company market share analysis, 2023
Fig. 46 Strategic framework